This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 5 for:    Tralokinumab atopic
Previous Study | Return to List | Next Study

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis (D2213C00001)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT02347176
First received: January 5, 2015
Last updated: May 11, 2017
Last verified: April 2017
  Purpose
The aim of the study is to evaluate the efficacy and safety of tralokinumab in adults with atopic dermatitis

Condition Intervention Phase
Atopic Dermatitis Other: Placebo Biological: Tralokinumab Dose 1 Biological: Tralokinumab Dose 2 Biological: Tralokinumab Dose 3 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12 [ Time Frame: Week 12 ]
    EASI evaluates 4 natural anatomical regions for severity and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The maximum total score is 72, with higher values indicating more severe disease. The data presented here is Adjusted mean change after excluding the data from participants who took prohibited medications.

  • Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline at Week 12 [ Time Frame: Week 12 ]
    The IGA allows investigators to assess overall disease severity at one given time point and consists of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease, and 5 = very severe disease). A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.


Secondary Outcome Measures:
  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) [ Time Frame: From Study Drug Administration to Week 22 ]
    An adverse event (AE) present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug until Week 22. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect in the offspring of a participant who received Tralokinumab. Treatment-emergent adverse events between administration of investigational product and Week 22 that were absent before treatment or that worsened relative to pre-treatment state.

  • Number of Participants With Vital Signs and Physical Examination Abnormalities Reported as Treatment Emergent Adverse Events [ Time Frame: From Study Drug Administration to Week 22 ]
    Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. TEAEs were present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug until Week 22.

  • Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment Emergent Adverse Events [ Time Frame: From Study Drug Administration to Week 22 ]
    An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Treatment-emergent adverse events between first dose of study drug and 10 weeks after the last dose that were absent before treatment or that worsened relative to pre-treatment state. Laboratory evaluations (haematology, serum chemistry and urinalysis) of blood and urine samples were performed.

  • Number of Participants With Electrocardiogram (ECG) Abnormalities Reported as Treatment Emergent Adverse Events [ Time Frame: From Study Drug Administration to Week 22 ]
    AEs observed in participants with clinically significant ECG abnormalities were assessed. ECG parameters included heart rate, RR, PR, QRS and QT intervals. Treatment-emergent adverse events between administration of investigational product and Week 22 that were absent before treatment or that worsened relative to pre-treatment state.

  • Percentage of Participants Achieving 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12 [ Time Frame: Week 12 ]
    EASI50 responder is defined as a participant who achieves at least a 50% reduction in EASI score from baseline.

  • Absolute Change From Baseline in Scoring of Atopic Dermatitis (SCORAD) at Week 12 [ Time Frame: Week 12 ]
    The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of AD. The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The maximum total score is 103, with higher values indicating more severe disease. The data presented here is Adjusted mean change after excluding the data from participants who took prohibited medications.

  • Percentage of Participants Achieving 50 Percent (%) Reduction From Baseline in SCORAD at Week 12 [ Time Frame: Week 12 ]
    SCORAD 50 responder is defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.

  • Change From Baseline in Pruritus Numeric Rating Scale (NRS) (7-day Mean Score) at Week 12 [ Time Frame: Week 12 ]
    Pruritus assessed using an NRS (0 - 10) with 0= no itch and 10= worst imaginable itch. Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated. The data presented here is Adjusted mean change after excluding the data from participants who took prohibited medications.


Enrollment: 306
Actual Study Start Date: January 23, 2015
Study Completion Date: February 5, 2016
Primary Completion Date: November 27, 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo will be administered subcutaneously to participants.
Other: Placebo
Subcutaneous injection with placebo
Experimental: Tralokinumab Dose 1
Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
Biological: Tralokinumab Dose 1
Subcutaneous injection with tralokinumab
Experimental: Tralokinumab Dose 2
Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
Biological: Tralokinumab Dose 2
Subcutaneous injection with tralokinumab
Experimental: Tralokinumab Dose 3
Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
Biological: Tralokinumab Dose 3
Subcutaneous injection with tralokinumab

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Physician diagnosis of atopic dermatitis for > 1 year
  • Atopic dermatitis involvement of ≥ 10% body surface area
  • EASI score of ≥ 12
  • SCORAD of ≥ 25
  • IGA score of ≥ 3
  • Effective birth control in line with protocol details

Exclusion Criteria:

  • History of anaphylaxis following any biologic therapy
  • Hepatitis B, C or HIV
  • Pregnant or breastfeeding
  • History of cancer
  • Previous receipt of tralokinumab
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02347176

  Show 52 Study Locations
Sponsors and Collaborators
MedImmune LLC
  More Information

Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT02347176     History of Changes
Other Study ID Numbers: D2213C00001
Study First Received: January 5, 2015
Results First Received: May 11, 2017
Last Updated: May 11, 2017

Additional relevant MeSH terms:
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017